International Consensus Development International guidelines have shown similar evolution toward continuation with risk mitigation (Table 2)
In this blog, we delve into the relationship between glutathione and fatty liver disease, uncovering the complexities and nuances that define its role in liver health
But in the beginning of last year, we, we said, no, it has to be for a diabetes prescription. -Senior Human Resources Leader, large services organization The use of GLP-1 agonists was higher than expected for many large employers including for over half (59%) of employers over 5,000 workers Since then, many larger employers covering GLP-1 agonists for weight loss reported higher than expected use of the medications and significant impacts on their prescription spending
According to estimates from MedPAC, negotiated rebates for diabetic therapy were equal to or greater than 50% in 2023
Finally, a retrospective cohort study compared 1775 matched pairs of SGLT2i users and nonusers with SLE and type 2 diabetes from the TriNetX database and found that use of SGLT2i was associated with significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use 8 9,10
